The Haywain: Anti-synthetase Antibodies in Patients with Inflammatory Diseases: Targeting Monocytes or Neutrophils?

Author(s): Bob Meek, Ger T. Rijkers*

Journal Name: Current Medicinal Chemistry

Volume 27 , Issue 17 , 2020

DOI : 10.2174/0929867326666191128141215

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Abstract:

Autoantibiodies against aminoacyl-tRNA synthetases are found in patients suffering from a wide range of autoimmune and inflammatory disorders. Recent data indicate that these antibodies are directed against splice-variants of synthetase genes, the so-called catalytic nulls. Latter molecules have cytokine-like functions and are involved in the regulation of the activation of lymphocytes, monocytes and granulocytes. The potential role of anti-synthetase antibodies as a diagnostic tool and a target for therapeutic interventions is discussed.

Keywords: Anti-synthetase, dermatomyositis, polymyositis, interstitial lung disease, aminoacyl-tRNA, inflammatory diseases.

[1]
Fritzler, M.J. Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing. Autoimmun. Rev., 2016, 15(3), 272-280.
[http://dx.doi.org/10.1016/j.autrev.2015.12.002] [PMID: 26687321]
[2]
Cooper, G.S.; Stroehla, B.C. The epidemiology of autoimmune diseases. Autoimmun. Rev., 2003, 2(3), 119-125.
[http://dx.doi.org/10.1016/S1568-9972(03)00006-5] [PMID: 12848952]
[3]
Gaubitz, M. Epidemiology of connective tissue disorders. Rheumatology (Oxford), 2006, 45(Suppl. 3), iii3-iii4.
[http://dx.doi.org/10.1093/rheumatology/kel282] [PMID: 16987829]
[4]
Chan, E.K.; Damoiseaux, J.; Carballo, O.G.; Conrad, K.; de Melo Cruvinel, W.; Francescantonio, P.L.; Fritzler, M.J.; Garcia-De La Torre, I.; Herold, M.; Mimori, T.; Satoh, M.; von Mühlen, C.A.; Andrade, L.E. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015. Front. Immunol., 2015, 6, 412.
[http://dx.doi.org/10.3389/fimmu.2015.00412] [PMID: 26347739]
[5]
Selmi, C.; Ceribelli, A.; Generali, E.; Scirè, C.A.; Alborghetti, F.; Colloredo, G.; Porrati, L.; Achenza, M.I.; De Santis, M.; Cavaciocchi, F.; Massarotti, M.; Isailovic, N.; Paleari, V.; Invernizzi, P.; Matthias, T.; Zucchi, A.; Meroni, P.L. Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmun. Rev., 2016, 15(2), 162-166.
[http://dx.doi.org/10.1016/j.autrev.2015.10.007] [PMID: 26524640]
[6]
Fang, P.; Guo, M. Structural characterization of human aminoacyl-tRNA synthetases for translational and nontranslational functions. Methods, 2017, 113, 83-90.
[http://dx.doi.org/10.1016/j.ymeth.2016.11.014] [PMID: 27887987]
[7]
Nishikai, M.; Reichlin, M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum., 1980, 23(8), 881-888.
[http://dx.doi.org/10.1002/art.1780230802] [PMID: 7406938]
[8]
Mathews, M.B.; Reichlin, M.; Hughes, G.R.; Bernstein, R.M. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J. Exp. Med., 1984, 160(2), 420-434.
[http://dx.doi.org/10.1084/jem.160.2.420] [PMID: 6206177]
[9]
Targoff, I.N. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J. Immunol., 1990, 144(5), 1737-1743.
[PMID: 2307838]
[10]
Satoh, M.; Tanaka, S.; Ceribelli, A.; Calise, S.J.; Chan, E.K. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin. Rev. Allergy Immunol., 2017, 52(1), 1-19.
[http://dx.doi.org/10.1007/s12016-015-8510-y] [PMID: 26424665]
[11]
Lega, J.C.; Fabien, N.; Reynaud, Q.; Durieu, I.; Durupt, S.; Dutertre, M.; Cordier, J.F.; Cottin, V. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun. Rev., 2014, 13(9), 883-891.
[http://dx.doi.org/10.1016/j.autrev.2014.03.004] [PMID: 24704867]
[12]
Ghirardello, A.; Bassi, N.; Palma, L.; Borella, E.; Domeneghetti, M.; Punzi, L.; Doria, A. Autoantibodies in polymyositis and dermatomyositis. Curr. Rheumatol. Rep., 2013, 15(6), 335.
[http://dx.doi.org/10.1007/s11926-013-0335-1] [PMID: 23591825]
[13]
Hamaguchi, Y.; Fujimoto, M.; Matsushita, T.; Kaji, K.; Komura, K.; Hasegawa, M.; Kodera, M.; Muroi, E.; Fujikawa, K.; Seishima, M.; Yamada, H.; Yamada, R.; Sato, S.; Takehara, K.; Kuwana, M. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One, 2013, 8(4) e60442
[http://dx.doi.org/10.1371/journal.pone.0060442] [PMID: 23573256]
[14]
Bohan, A.; Peter, J.B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med., 1975, 292(7), 344-347.
[http://dx.doi.org/10.1056/NEJM197502132920706] [PMID: 1090839]
[15]
Bohan, A.; Peter, J.B. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med., 1975, 292(8), 403-407.
[http://dx.doi.org/10.1056/NEJM197502202920807] [PMID: 1089199]
[16]
Findlay, A.R.; Goyal, N.A.; Mozaffar, T. An overview of polymyositis and dermatomyositis. Muscle Nerve, 2015, 51(5), 638-656.
[http://dx.doi.org/10.1002/mus.24566] [PMID: 25641317]
[17]
Hozumi, H.; Fujisawa, T.; Nakashima, R.; Johkoh, T.; Sumikawa, H.; Murakami, A.; Enomoto, N.; Inui, N.; Nakamura, Y.; Hosono, Y.; Imura, Y.; Mimori, T.; Suda, T. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir. Med., 2016, 121, 91-99.
[http://dx.doi.org/10.1016/j.rmed.2016.10.019] [PMID: 27888997]
[18]
Chatterjee, S.; Prayson, R.; Farver, C. Antisynthetase syndrome: not just an inflammatory myopathy. Cleve. Clin. J. Med., 2013, 80(10), 655-666.
[http://dx.doi.org/10.3949/ccjm.80a.12171] [PMID: 24085811]
[19]
Yura, H.; Sakamoto, N.; Satoh, M.; Ishimoto, H.; Hanaka, T.; Ito, C.; Hasegawa, T.; Tanaka, S.; Miyamura, T.; Nakashima, S.; Hara, A.; Kakugawa, T.; Oda, K.; Kido, T.; Obase, Y.; Ishimatsu, Y.; Yatera, K.; Kawakami, A.; Mukae, H. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia. Respir. Med., 2017, 132, 189-194.
[http://dx.doi.org/10.1016/j.rmed.2017.10.020] [PMID: 29229096]
[20]
Pinal-Fernandez, I.; Casal-Dominguez, M.; Huapaya, J.A.; Albayda, J.; Paik, J.J.; Johnson, C.; Silhan, L.; Christopher-Stine, L.; Mammen, A.L.; Danoff, S.K. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford), 2017, 56(6), 999-1007.
[http://dx.doi.org/10.1093/rheumatology/kex021] [PMID: 28339994]
[21]
Saketkoo, L.A.; Mittoo, S.; Frankel, S.; LeSage, D.; Sarver, C.; Phillips, K.; Strand, V.; Matteson, E.L. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. J. Rheumatol., 2014, 41(4), 792-798.
[http://dx.doi.org/10.3899/jrheum.131251] [PMID: 24488412]
[22]
Debray, M.P.; Borie, R.; Revel, M.P.; Naccache, J.M.; Khalil, A.; Toper, C.; Israel-Biet, D.; Estellat, C.; Brillet, P.Y. Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. Eur. J. Radiol., 2015, 84(3), 516-523.
[http://dx.doi.org/10.1016/j.ejrad.2014.11.026] [PMID: 25541020]
[23]
Strek, M.E.; Costabel, U. Interstitial pneumonia with autoimmune features: a critical appraisal of the new definition. Curr. Opin. Pulm. Med., 2016, 22(5), 442-449.
[http://dx.doi.org/10.1097/MCP.0000000000000298] [PMID: 27379968]
[24]
Fischer, A.; Antoniou, K.M.; Brown, K.K.; Cadranel, J.; Corte, T.J.; du Bois, R.M.; Lee, J.S.; Leslie, K.O.; Lynch, D.A.; Matteson, E.L.; Mosca, M.; Noth, I.; Richeldi, L.; Strek, M.E.; Swigris, J.J.; Wells, A.U.; West, S.G.; Collard, H.R.; Cottin, V. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur. Respir. J., 2015, 46(4), 976-987.
[http://dx.doi.org/10.1183/13993003.00150-2015] [PMID: 26160873]
[25]
Fischer, A.; du Bois, R. Interstitial lung disease in connective tissue disorders. Lancet, 2012, 380(9842), 689-698.
[http://dx.doi.org/10.1016/S0140-6736(12)61079-4] [PMID: 22901890]
[26]
Tzelepis, G.E.; Toya, S.P.; Moutsopoulos, H.M. Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur. Respir. J., 2008, 31(1), 11-20.
[http://dx.doi.org/10.1183/09031936.00060107] [PMID: 18166591]
[27]
Mittoo, S.; Gelber, A.C.; Christopher-Stine, L.; Horton, M.R.; Lechtzin, N.; Danoff, S.K. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir. Med., 2009, 103(8), 1152-1158.
[http://dx.doi.org/10.1016/j.rmed.2009.02.009] [PMID: 19304475]
[28]
Castelino, F.V.; Varga, J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res. Ther., 2010, 12(4), 213.
[http://dx.doi.org/10.1186/ar3097] [PMID: 20735863]
[29]
Lo, W.S.; Gardiner, E.; Xu, Z.; Lau, C.F.; Wang, F.; Zhou, J.J.; Mendlein, J.D.; Nangle, L.A.; Chiang, K.P.; Yang, X.L.; Au, K.F.; Wong, W.H.; Guo, M.; Zhang, M.; Schimmel, P. Human tRNA synthetase catalytic nulls with diverse functions. Science, 2014, 345(6194), 328-332.
[http://dx.doi.org/10.1126/science.1252943] [PMID: 25035493]
[30]
Zhou, J.J.; Wang, F.; Xu, Z.; Lo, W.S.; Lau, C.F.; Chiang, K.P.; Nangle, L.A.; Ashlock, M.A.; Mendlein, J.D.; Yang, X.L.; Zhang, M.; Schimmel, P. Secreted histidyl-tRNA synthetase splice variants elaborate major epitopes for autoantibodies in inflammatory myositis. J. Biol. Chem., 2014, 289(28), 19269-19275.
[http://dx.doi.org/10.1074/jbc.C114.571026] [PMID: 24898250]
[31]
Schimmel, P. The emerging complexity of the tRNA world: mammalian tRNAs beyond protein synthesis. Nat. Rev. Mol. Cell Biol., 2018, 19(1), 45-58.
[http://dx.doi.org/10.1038/nrm.2017.77] [PMID: 28875994]
[32]
Wakasugi, K.; Schimmel, P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science, 1999, 284(5411), 147-151.
[http://dx.doi.org/10.1126/science.284.5411.147] [PMID: 10102815]
[33]
Howard, O.M.; Dong, H.F.; Yang, D.; Raben, N.; Nagaraju, K.; Rosen, A.; Casciola-Rosen, L.; Härtlein, M.; Kron, M.; Yang, D.; Yiadom, K.; Dwivedi, S.; Plotz, P.H.; Oppenheim, J.J. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J. Exp. Med., 2002, 196(6), 781-791.
[http://dx.doi.org/10.1084/jem.20020186] [PMID: 12235211]
[34]
Park, S.G.; Schimmel, P.; Kim, S. Aminoacyl tRNA synthetases and their connections to disease. Proc. Natl. Acad. Sci. USA, 2008, 105(32), 11043-11049.
[http://dx.doi.org/10.1073/pnas.0802862105] [PMID: 18682559]
[35]
Sajish, M.; Schimmel, P. A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature, 2015, 519(7543), 370-373.
[http://dx.doi.org/10.1038/nature14028] [PMID: 25533949]
[36]
Mammen, A.L. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat. Rev. Neurol., 2011, 7(6), 343-354.
[http://dx.doi.org/10.1038/nrneurol.2011.63] [PMID: 21654717]
[37]
Mathews, M.B.; Bernstein, R.M. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature, 1983, 304(5922), 177-179.
[http://dx.doi.org/10.1038/304177a0] [PMID: 6866113]
[38]
Martin, A.; Shulman, M.J.; Tsui, F.W. Epitope studies indicate that histidyl-tRNA synthetase is a stimulating antigen in idiopathic myositis. FASEB J., 1995, 9(12), 1226-1233.
[http://dx.doi.org/10.1096/fasebj.9.12.7672516] [PMID: 7672516]
[39]
Raben, N.; Nichols, R.; Dohlman, J.; McPhie, P.; Sridhar, V.; Hyde, C.; Leff, R.; Plotz, P. A motif in human histidyl-tRNA synthetase which is shared among several aminoacyl-tRNA synthetases is a coiled-coil that is essential for enzymatic activity and contains the major autoantigenic epitope. J. Biol. Chem., 1994, 269(39), 24277-24283.
[PMID: 7523371]
[40]
Miller, F.W.; Twitty, S.A.; Biswas, T.; Plotz, P.H. Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J. Clin. Invest., 1990, 85(2), 468-475.
[http://dx.doi.org/10.1172/JCI114461] [PMID: 1688885]
[41]
Xu, Z.; Wei, Z.; Zhou, J.J.; Ye, F.; Lo, W.S.; Wang, F.; Lau, C.F.; Wu, J.; Nangle, L.A.; Chiang, K.P.; Yang, X.L.; Zhang, M.; Schimmel, P. Internally deleted human tRNA synthetase suggests evolutionary pressure for repurposing. Structure, 2012, 20(9), 1470-1477.
[http://dx.doi.org/10.1016/j.str.2012.08.001] [PMID: 22958643]
[42]
Porto, B.N.; Stein, R.T. Neutrophil extracellular traps in pulmonary diseases: too much of a good thing? Front. Immunol., 2016, 7, 311.
[http://dx.doi.org/10.3389/fimmu.2016.00311] [PMID: 27574522]
[43]
Zhang, S.; Shu, X.; Tian, X.; Chen, F.; Lu, X.; Wang, G. Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications. Clin. Exp. Immunol., 2014, 177(1), 134-141.
[http://dx.doi.org/10.1111/cei.12319] [PMID: 24611519]
[44]
Ascherman, D.P. Role of Jo-1 in the immunopathogenesis of the anti-synthetase syndrome. Curr. Rheumatol. Rep., 2015, 17(9), 56.
[http://dx.doi.org/10.1007/s11926-015-0532-1] [PMID: 26210509]
[45]
Williamson, D.A.; Carter, G.P.; Howden, B.P. Current and emerging topical antibacterials and antiseptics: agents, action, and resistance patterns. Clin. Microbiol. Rev., 2017, 30(3), 827-860.
[http://dx.doi.org/10.1128/CMR.00112-16] [PMID: 28592405]
[46]
Yao, P.; Fox, P.L. Aminoacyl-tRNA synthetases in medicine and disease. EMBO Mol. Med., 2013, 5(3), 332-343.
[http://dx.doi.org/10.1002/emmm.201100626] [PMID: 23427196]
[47]
Saunders, J.; Maki, K.; Koski, R.; Nybo, S.E. Tavaborole, Efinaconazole, and Luliconazole: Three new antimycotic agents for the treatment of dermatophytic fungi. J. Pharm. Pract., 2017, 30(6), 621-630.
[http://dx.doi.org/10.1177/0897190016660487] [PMID: 27488125]
[48]
Luo, Y.; Xie, X.; Luo, D.; Wang, Y.; Gao, Y. The role of halofuginone in fibrosis: more to be explored? J. Leukoc. Biol., 2017, 102(6), 1333-1345.
[http://dx.doi.org/10.1189/jlb.3RU0417-148RR] [PMID: 28986385]
[49]
Shibata, A.; Kuno, M.; Adachi, R.; Sato, Y.; Hattori, H.; Matsuda, A.; Okuzono, Y.; Igaki, K.; Tominari, Y.; Takagi, T.; Yabuki, M.; Okaniwa, M. Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy. PLoS One, 2017, 12(10) e0186587
[http://dx.doi.org/10.1371/journal.pone.0186587] [PMID: 29065190]
[50]
Nangle, L.A.; Tong, Y.; Crampton, S.P.; Adams, R.A.; Chiang, K.P.; Mertsching, E.; Taylor, K.; Ogilvie, K.M.; McKew, J.C.; Ashlock, M.A.; Schimmel, P. The resokine pathway is implicated in the pathology of interstitial lung disease. Am. J. Respir. Crit. Care Med., 2017, 195, A7068.
[51]
Ogilvie, K.M.; Do, M.T.; Chiang, K.P.; Adams, R.A.; Crampton, S.P.; Nangle, L.A.; Cubitt, A.B.; McKew, J.C.; Ashlock, M.A.; Mendlein, J.D. Resokine modulates immune cell infiltration into the lung and provides therapeutic activity in a bleomycin-induced lung fibrosis model. Am. J. Respir. Crit. Care Med., 2017, 195, A6428.
[52]
Evaluation of the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous ATYR1923 in healthy volunteers. Australian New Zealand Clinical trials registry, 2019. Available at:. https://www. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373652 (Accessed Date: November 2, 2019).
[53]
McElvaney, O.J.; Horan, D.; Franciosi, A.N.; Gunaratnam, C.; McElvaney, N.G. Pulmonary alveolar proteinosis. QJM, 2018, 111(3), 185-186.
[http://dx.doi.org/10.1093/qjmed/hcx235] [PMID: 29240908]
[54]
Nishimura, M.; Yamaguchi, E.; Takahashi, A.; Asai, N.; Katsuda, E.; Ohta, T.; Ohtsuka, Y.; Kosaka, K.; Matsubara, A.; Tanaka, H.; Yokoe, N.; Kubo, A.; Konno, S.; Baba, K. Clinical significance of serum anti-GM-CSF autoantibody levels in autoimmune pulmonary alveolar proteinosis. Biomarkers Med., 2018, 12(2), 151-159.
[http://dx.doi.org/10.2217/bmm-2017-0362] [PMID: 29202602]
[55]
The haywain. Museo del Prado. Available at:. http://boschproject.org/#/artworks/The_Haywain_Prado (Accessed Date : October 2019.).


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 17
Year: 2020
Published on: 05 June, 2020
Page: [2863 - 2871]
Pages: 9
DOI: 10.2174/0929867326666191128141215
Price: $65

Article Metrics

PDF: 17
HTML: 4



Related Article(s)

Most Downloaded Article(s)